The present disclosure provides: one or more salts or crystalline forms of 3-deuteromitragynine of Formula I; and one or more salts or crystalline forms of mitragynine of Formula II. Pharmaceutical compositions comprising salts and crystalline forms of Formulae I and II and methods of treatment are also disclosed. Methods of preparing and purifying the salts of Formulae I and II are further disclosed.
The present disclosure provides: one or more salts or crystalline forms of 3-deuteromitragynine of Formula I; and one or more salts or crystalline forms of mitragynine of Formula II. Pharmaceutical compositions comprising salts and crystalline forms of Formulae I and II and methods of treatment are also disclosed. Methods of preparing and purifying the salts of Formulae I and II are further disclosed.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
The present disclosure relates to a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
The present disclosure relates to a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
3.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF
The present disclosure provides a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
4.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF
The present disclosure provides a compound having the structure: Formula (I) wherein R1 is —H or -(alkyl); R2 is -(alkyl)-CO2H or -(alkyl)-CO2-(alkyl); R3 is —H or -(alkyl); and X is —Br or —I, or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington’s disease, Rett syndrome, and CDKL5 disorder.
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure provides: one or more salts or crystalline forms of 3-deuteromitragynine of Formula I; and one or more salts or crystalline forms of mitragynine of Formula II. Pharmaceutical compositions comprising salts and crystalline forms of Formulae I and II and methods of treatment are also disclosed. Methods of preparing and purifying the salts of Formulae I and II are further disclosed.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
The present disclosure relates to a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/00 - Drugs for disorders of the nervous system
7.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR
The present disclosure provides a compound having the structure: Formula (I) or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
C07D 281/12 - Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
8.
CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR
1233 is –H or –(alkyl); and X is -Br or -I, or a pharmaceutically acceptable salt or ester thereof, for treating or preventing a neurological disorder, including Huntington's disease, Rett syndrome, and CDKL5 disorder.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/00 - Drugs for disorders of the nervous system
patents
